Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

6.215 +0.275 (+4.63%)
Streaming Delayed Price Updated: 3:29 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 754,178
Open 5.900
Bid (Size) 6.210 (700)
Ask (Size) 6.220 (800)
Prev. Close 5.940
Today's Range 5.870 - 6.250
52wk Range 4.000 - 7.650
Shares Outstanding 54,191,361
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Abeona Therapeutics Q2 2026 Earnings Call Transcript ↗
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Abeona Therapeutics Q2 Earnings Call Highlights ↗
Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that... 
Via MarketBeat
Topics Earnings

Performance

YTD
+17.0%
+17.0%
1 Month
-4.1%
-4.1%
3 Month
+15.7%
+15.7%
6 Month
+23.3%
+23.3%
1 Year
-10.1%
-10.1%

More News

Read More
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025 ↗
Via Chartmill
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Abeona Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network ↗
Via Benzinga
News headline image
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of First Quarter Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 6.215
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 08/18/26 03:29 PM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 336.80M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 337M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.